Actuate Therapeutics Files S-1 for Public Offering
Ticker: ACTU · Form: S-1 · Filed: Jul 25, 2025 · CIK: 1652935
| Field | Detail |
|---|---|
| Company | Actuate Therapeutics, Inc. (ACTU) |
| Form Type | S-1 |
| Filed Date | Jul 25, 2025 |
| Risk Level | high |
| Sentiment | bearish |
Sentiment: bearish
Topics: S-1 Filing, Biotechnology, Pharmaceuticals, IPO, Emerging Growth Company, Smaller Reporting Company, Drug Development
TL;DR
**Actuate Therapeutics is going public, but without financials, it's a high-risk bet on future drug pipeline success.**
AI Summary
Actuate Therapeutics, Inc. filed an S-1 registration statement on July 25, 2025, indicating its intent to go public. The company, a pharmaceutical preparations firm (SIC 2834), is based in Fort Worth, Texas, and was formerly known as Apotheca Therapeutics, Inc. until September 11, 2015. As a non-accelerated filer and a smaller reporting company, ACTUATE will likely face less stringent reporting requirements, which could impact investor transparency. The filing does not disclose specific revenue or net income figures, but as a pre-IPO biotech, it is presumed to be pre-revenue or in early clinical stages, focusing on drug development. Key risks include the inherent uncertainties of clinical trials and regulatory approvals for its pharmaceutical products. The strategic outlook involves leveraging the public markets to fund its drug development pipeline, with Daniel Schmitt serving as President and CEO. The company's business address is 1751 River Run, Suite 400, Fort Worth, Texas 76107, with a business phone of (817) 887-8455.
Why It Matters
This S-1 filing signals Actuate Therapeutics' move to access public capital, crucial for funding its pharmaceutical research and development pipeline in a highly competitive biotech landscape. For investors, it represents an early opportunity to evaluate a potential new player in the drug development sector, though the lack of detailed financials in this initial summary means significant due diligence will be required. Employees could see increased job security and potential equity upside, while customers (future patients) might benefit from new therapeutic options if Actuate's drug candidates succeed. The broader market gains another biotech entrant, intensifying competition among pharmaceutical companies vying for market share and innovation.
Risk Assessment
Risk Level: high — The risk level is high because the S-1 filing is for a pharmaceutical preparations company (SIC 2834) that is likely pre-revenue or in early clinical stages, as specific financial figures for revenue and net income are not provided in the summary. The inherent uncertainties of drug development, including clinical trial failures and regulatory hurdles, pose significant risks to future profitability and success. The company's status as a 'smaller reporting company' also suggests a less mature operational and financial profile.
Analyst Insight
Investors should approach Actuate Therapeutics with extreme caution, recognizing the significant speculative nature of early-stage biotech investments. Wait for the full S-1 filing to be publicly available and thoroughly analyze the company's drug pipeline, clinical trial data, management team, and detailed financial statements before considering any investment. This is not a 'buy now' situation.
Financial Highlights
- debt To Equity
- N/A
- revenue
- $0
- operating Margin
- N/A
- total Assets
- $0
- total Debt
- $0
- net Income
- $0
- eps
- $0
- gross Margin
- N/A
- cash Position
- $0
- revenue Growth
- N/A
Key Numbers
- 2025-07-25 — S-1 Filing Date (Date Actuate Therapeutics, Inc. filed its registration statement with the SEC.)
- 333-288952 — SEC File Number (Unique identifier for Actuate Therapeutics' S-1 registration statement.)
- 0001652935 — Central Index Key (CIK) (Unique identifier for Actuate Therapeutics, Inc. with the SEC.)
- 2834 — Standard Industrial Classification (SIC) Code (Indicates the company operates in 'Pharmaceutical Preparations'.)
- 47-3044785 — IRS Employer Identification Number (EIN) (Tax identification number for Actuate Therapeutics, Inc.)
- 1751 River Run, Suite 400 — Business Address (Principal executive offices of Actuate Therapeutics, Inc. in Fort Worth, Texas.)
- 817-887-8455 — Business Phone Number (Contact number for Actuate Therapeutics, Inc.)
- 2015-09-11 — Date of Name Change (Date the company changed its name from Apotheca Therapeutics, Inc. to Actuate Therapeutics, Inc.)
Key Players & Entities
- ACTUATE THERAPEUTICS, INC. (company) — Registrant filing S-1
- Daniel Schmitt (person) — President and Chief Executive Officer of Actuate Therapeutics, Inc.
- Janet Spreen, Esq. (person) — Legal counsel from Baker & Hostetler LLP
- Baker & Hostetler LLP (company) — Legal firm representing Actuate Therapeutics, Inc.
- Securities and Exchange Commission (regulator) — Regulatory body for S-1 filing
- Apotheca Therapeutics, Inc. (company) — Former name of Actuate Therapeutics, Inc.
- Fort Worth, Texas (company) — Location of Actuate Therapeutics' principal executive offices
- Delaware (company) — State of incorporation for Actuate Therapeutics, Inc.
- July 25, 2025 (dollar_amount) — Date of S-1 filing
- 817-887-8455 (dollar_amount) — Business phone number of Actuate Therapeutics, Inc.
FAQ
What is Actuate Therapeutics, Inc. and what does it do?
Actuate Therapeutics, Inc. is a pharmaceutical preparations company, identified by SIC Code 2834, based in Fort Worth, Texas. It is engaged in the development of pharmaceutical products, as indicated by its S-1 filing on July 25, 2025, to register securities for public sale.
When did Actuate Therapeutics, Inc. file its S-1 registration statement?
Actuate Therapeutics, Inc. filed its S-1 registration statement with the SEC on July 25, 2025, under accession number 0001683168-25-005402, to register securities under the Securities Act of 1933.
Who is the CEO of Actuate Therapeutics, Inc.?
Daniel Schmitt is the President and Chief Executive Officer of Actuate Therapeutics, Inc. His business address is 1751 River Run, Suite 400, Fort Worth, Texas 76107, and his phone number is (817) 887-8455.
What is the primary business address of Actuate Therapeutics, Inc.?
The principal executive offices of Actuate Therapeutics, Inc. are located at 1751 River Run, Suite 400, Fort Worth, Texas 76107. The business phone number is (817) 887-8455.
What was Actuate Therapeutics, Inc. formerly known as?
Actuate Therapeutics, Inc. was formerly known as Apotheca Therapeutics, Inc. The company changed its name on September 11, 2015, as stated in the S-1 filing.
What is the risk level for investing in Actuate Therapeutics, Inc. based on this S-1 summary?
The risk level is high for investing in Actuate Therapeutics, Inc. at this stage. The company is a pharmaceutical preparations firm, likely pre-revenue, and the S-1 summary does not provide specific financial performance data, indicating significant reliance on future drug development success and regulatory approvals.
What type of filer is Actuate Therapeutics, Inc. with the SEC?
Actuate Therapeutics, Inc. is designated as a non-accelerated filer and a smaller reporting company. These designations typically mean less extensive reporting requirements compared to larger, more established public companies.
Who is the legal counsel for Actuate Therapeutics, Inc. regarding this S-1 filing?
Janet Spreen, Esq., from Baker & Hostetler LLP, located at 127 Public Square, Suite 2000, Cleveland, Ohio 44114, is listed as legal counsel for Actuate Therapeutics, Inc. for this S-1 filing.
What is the significance of Actuate Therapeutics, Inc. being an 'emerging growth company'?
While the summary indicates 'emerging growth company' is checked, this status allows Actuate Therapeutics, Inc. to take advantage of certain scaled-back disclosure requirements and exemptions from various reporting obligations under the JOBS Act, potentially reducing the costs and burdens of being a public company.
What should investors consider before investing in Actuate Therapeutics, Inc.?
Investors should consider the high inherent risks of early-stage pharmaceutical companies, the lack of detailed financial information in this initial summary, and the company's status as a smaller reporting company. A thorough review of the complete S-1 filing, including its drug pipeline, clinical data, and financial statements, is crucial before making any investment decisions.
Risk Factors
- Clinical Trial and Regulatory Approval Uncertainty [high — regulatory]: The company's success is heavily dependent on the successful development and regulatory approval of its pharmaceutical products. This process is inherently uncertain, lengthy, and expensive, with no guarantee of success. Failure to obtain regulatory approval for any of its drug candidates would significantly impact the company's ability to generate revenue.
- Dependence on Future Financing [high — financial]: As a pre-revenue company, Actuate Therapeutics will require substantial capital to fund its ongoing research and development activities, clinical trials, and potential commercialization. The company's ability to secure future financing through equity or debt offerings, or strategic partnerships, is critical for its survival and growth.
- Reliance on Key Personnel [medium — operational]: The company's ability to execute its business plan relies on the continued service of its key management team, including Daniel Schmitt, President and CEO. The loss of any key personnel could disrupt operations and negatively impact the company's prospects.
- Competition in the Pharmaceutical Industry [medium — market]: The pharmaceutical industry is highly competitive, with numerous companies developing drugs for similar therapeutic areas. Actuate Therapeutics faces competition from established pharmaceutical companies and other biotechnology firms, which could affect its market share and pricing power.
- Intellectual Property Protection [medium — legal]: The company's ability to protect its intellectual property, including patents and trade secrets, is crucial for its long-term success. Challenges to its intellectual property rights or failure to secure adequate patent protection could adversely affect its competitive position.
Industry Context
Actuate Therapeutics operates within the highly competitive pharmaceutical preparations industry (SIC 2834). This sector is characterized by significant research and development investment, lengthy product development cycles, and stringent regulatory oversight. Key trends include the ongoing pursuit of novel therapeutics, advancements in biotechnology, and increasing demand for treatments for various diseases. The industry landscape includes large, established pharmaceutical giants as well as numerous smaller biotech firms, all vying for market share and therapeutic breakthroughs.
Regulatory Implications
As a pharmaceutical company, Actuate Therapeutics is subject to extensive regulation by bodies such as the Food and Drug Administration (FDA). The S-1 filing highlights the inherent risks associated with clinical trials and the lengthy, complex process of obtaining regulatory approval for drug candidates. Compliance with Good Manufacturing Practices (GMP) and other regulatory standards is critical throughout the drug development and commercialization lifecycle.
What Investors Should Do
- Scrutinize the clinical trial data and pipeline progression.
- Evaluate the company's cash burn rate and future financing needs.
- Assess the competitive landscape for each drug candidate.
- Consider the implications of being a non-accelerated and smaller reporting company.
Key Dates
- 2025-07-25: S-1 Filing Date — Indicates the company's intent to go public and begin the IPO process.
- 2015-09-11: Date of Name Change — The company was formerly known as Apotheca Therapeutics, Inc., highlighting a potential rebranding or strategic shift.
Glossary
- S-1 Registration Statement
- A form filed with the U.S. Securities and Exchange Commission (SEC) by companies planning to offer their securities to the public. It contains detailed information about the company's business, financial condition, and management. (This is the foundational document for Actuate Therapeutics' initial public offering (IPO), providing investors with essential information.)
- Non-accelerated filer
- A category of filer with the SEC that has less than $75 million in public float and has been a reporting company for at least 12 months. They have less stringent reporting requirements. (Indicates Actuate Therapeutics may have fewer disclosure obligations, potentially impacting transparency for investors.)
- Smaller reporting company
- A company with a public float of less than $250 million. Similar to non-accelerated filers, they have reduced disclosure requirements. (Further reinforces that Actuate Therapeutics may face less rigorous reporting, affecting the depth of information available to investors.)
- SIC Code 2834
- Standard Industrial Classification code for Pharmaceutical Preparations. This industry includes establishments primarily engaged in the manufacturing of medicinal and botanical drugs, pharmaceutical preparations, and related products. (Defines Actuate Therapeutics' core business as a pharmaceutical preparations company.)
- IPO
- Initial Public Offering. The first time a private company offers its shares to the public, allowing it to raise capital and become a publicly traded entity. (The S-1 filing signifies Actuate Therapeutics' intention to conduct an IPO.)
Year-Over-Year Comparison
As this is an initial S-1 filing, there is no prior filing to compare against. Therefore, a comparison of key metrics such as revenue growth, margin changes, or new risks relative to a previous year is not applicable at this stage. The S-1 represents the company's first comprehensive public disclosure of its business and financial condition as it prepares for an Initial Public Offering.
Filing Details
This Form S-1 (Form S-1) was filed with the SEC on July 25, 2025 by Daniel Schmitt regarding ACTUATE THERAPEUTICS, INC. (ACTU).